Back to results
US 2017/0291911 A1Published application
Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use
AssigneeAtrin Pharmaceuticals LLC
InventorsHenry Joseph Breslin, Oren Gilad, Gerhard Sperl, Eric J. Brown, Laura Butler
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.
Claims50
A compound of Formula (I) or Formula (II):
- wherein:
- A is CH, C—C1-6alkyl, C—C1-6haloalkyl, or N;
- B is CH, C—C1-6alkyl, C—C1-6haloalkyl, or N;
- ring D is phenylene or pyridylene;
- R11 is H or C1-6alkyl;
- R12 is H or C1-6alkyl;
- R13 is H or C1-6alkyl;
- R14 is OH, —OC1-30alkyl, —O-aryl, —O—C1-30alk-C(O)C1-30alkyl, —O—C1-30alk-C(O)NR15R16, —O-monosaccharide, —S—C1-30alkyl, a peptidyl moiety, an isopeptide moiety, or a peptidyl-isopeptide moiety;
- R15 and R16 are, independently, optionally substituted C1-30alkyl, C1-20alkenyl, aryl, arylalkyl, or C3-10cycloalkyl;
- Z′ is —SO2— or —C(O)—;
- Y′ is an alkylene;
- n is 1 or 2;
- each J1′ is, independently, H, halogen, optionally substituted —C1-6alkyl, optionally substituted C1-6haloalkyl, optionally substituted —C1-6alkoxy, NH2, NH-(optionally substituted C1-6 alkyl), N-(optionally substituted C1-6alkyl)(optionally substituted C1-6alkyl), —C1-6alk-NH-(optionally substituted C1-6alkyl), or —C1-6alk-NH—C0-6alk-(optionally substituted C3-6heterocycloalkyl);
- and
- L′ is a 7 to 17-membered linking group comprising an alkylene interrupted by 1, 2, 3, 4 or 5 heteroatom moieties selected from —O—, —NH—, —N(C1-6alkyl),
- —N(optionally substituted C1-6alkyl), and
- —N(C1-6alkyl)-O(optionally substituted C1-6alkyl);
- or a pharmaceutically acceptable salt thereof.
15 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.